Nosocomial Infection Treatment Market: Introduction
Nosocomial infection is termed as infection caused within 48 hours of hospital admission. Hence, it is also known as hospital-acquired infection. Patients in intensive care units (ICU) are more prone to hospital-acquired infections.
Read Report Overview – https://www.transparencymarketresearch.com/nosocomial-infection-treatment-market.html
About 90% hospital-acquired infections are bacterial infections. E. coli, P. aeruginosa, and S. aureus are the most common bacteria responsible for urinary and respiratory tract infections, wound, kidney, and blood infection. Excessive and misuse of antibiotics has led to increase in number of nosocomial infections.
Key Drivers and Opportunities of Global Nosocomial Infection Treatment Market
Increase in incidence of hospital-acquired infections is projected to boost the growth of the global nosocomial infection treatment market. According to the Centers for Disease Control and Prevention, an estimated 1.7 million infections and 99,000 deaths occur due to healthcare-acquired infections in hospitals in the U.S. each year.
Request Brochure of Report – https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=75837
Moreover, rise in prevalence of nosocomial infections such as urinary tract infection, tuberculosis, surgical wound infection, and respiratory tract infection is anticipated to fuel the growth of the global market. According to the Pharmacotherapy Self-Assessment Program: Hematology/Oncology, approximately 60% of women have symptomatic UTI during their lifetime and in the U.S., around 10% women have one or more than one UTI episodes each year. According to the World Health Organization, globally, an estimated 10 million people fell ill with tuberculosis in 2018. According to the Centers for Disease Control and Prevention, around 157,500 surgical site infections are reported in the U.S. each year.
Antibiotics are the most commonly prescribed treatments for nosocomial infections. Excessive use of antibiotics leads to microbial antibiotic resistance. Hence, development of new antibiotics is underway in order to overcome multiple drug resistance. For instance, in July 2019, the U.S. Food and Drug Administration approved the antibacterial drug, Recarbrio, for the treatment of complicated UTIs and complicated intra-abdominal infection in adults.
Request for Analysis of COVID-19 Impact on Nosocomial Infection Treatment Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=75837
In February 2018, Allergan received the U.S. Food and Drug Administration approval for New Drug Application of Avycaz. The drug was approved for the treatment of patients with ventilator-associated bacterial pneumonia and hospital-acquired bacterial pneumonia.
Increase in demand for new antibiotics for effective therapy presents considerable opportunity to manufacturers in the market
Rise in prevalence of nosocomial infections in developing countries creates lucrative opportunities in the global market. According to the Second Australian Atlas of Healthcare Variation, an estimated 73,777 hospitalizations for kidney and urinary tract infections were reported in Australia in 2014–2015.
Pre Book Nosocomial Infection Treatment Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=75837<ype=S
North America to Capture Major Share of Global Nosocomial Infection Treatment Market
North America is expected to account for major share of the global nosocomial infection treatment market during the forecast period due to presence of key players and product launch & approvals. Moreover, rise in prevalence of nosocomial infections is likely to fuel the growth of the market in the region. According to the American Urology Association, the estimated incidence of UTI is 0.5 to 0.7 per person per year in premenopausal women in the U.S.
The nosocomial infection treatment market in Asia Pacific is expected to grow at a rapid pace during the forecast period due to increase in awareness and surge in geriatric population.
Key Players Operating in Global Nosocomial Infection Treatment Market
The global nosocomial infection treatment market is highly consolidated due to the presence of key players. A large number of manufacturers hold major share in their respective regions. Growth strategies adopted by key players are likely fuel the growth of the global market. For instance, in July 2018, Nabriva Therapeutics plc acquired Zavante Therapeutics. This acquisition enabled the company to strengthen its leading positioning and develop new anti-infectives.
More Trending Reports by Transparency Market Research –
Primary Immunodeficiency Market: https://www.biospace.com/article/primary-immunodeficiency-market-advancements-in-genetic-management-and-next-generation-sequencing-technologies-to-aid-market-growth/
Read our Case study at https://www.transparencymarketresearch.com/casestudies/innovative-medical-device-manufacturing-start-up
About Us
Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Contact
Transparency Market Research,
90 State Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com/
